Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors

Abstract

CETP Inhibitors have improved solubility and bioavailability in a lipophilic vehicle comprising a digestible oil, a lipophilic solvent, or a surfactant. Preferred such compositions are self-emulsifying or self-microemulsifying, and comprise 1. a CETP inhibitor; 2. a cosolvent; 3. a surfactant having an HLB of 1 to 8; 4. a surfactant having an HLB of over 8 to 20; and 5. optionally, a digestible oil.

Description

FIELD OF THE INVENTION [0001] This invention relates to encapsulated formulations of cholesterol ester transfer protein (CETP) inhibitors for use in mammals, especially humans, which for mutations provide increased concentrations of CETP inhibitors for absorption, hence higher bioavailability. BACKGROUND OF THE INVENTION [0002] CETP inhibitors, as a class, are characterized by high binding activity. Such CETP inhibitors are generally hydrophobic, however, with the consequence that they have extremely low aqueous solubility and have low oral bioavailability. Such compounds have generally proven to be difficult to formulate for oral administration such that high bioavailabilities are achieved. [0003] Atherosclerosis and its associated coronary artery disease (CAD) is the leading cause of death in the industrialized world. Despite attempts to modify secondary risk factors (smoking, obesity, lack of exercise) and treatment of dyslipidemia with dietary modification and drug therapy, coro...

AI Technical Summary

Benefits of technology

This patent describes pharmaceutical compositions that contain a CETP inhibitor dissolved or dispersed in a liquid solution or emulsion. The solutions can be administered as oral liquids or capsules. The presence of surfactants can improve the solubility and bioavailability of the CETP inhibitor. The compositions can also contain a combination of a digestible oil and a surfactant to form a stable emulsion when mixed with water or other aqueous medium. The use of a cosolvent can increase the solubility of the CETP inhibitor. Overall, the patent provides a way to improve the oral bioavailability of CETP inhibitors and to increase the exposure in toxicology species.

Problems solved by technology

Such CETP inhibitors are generally hydrophobic, however, with the consequence that they have extremely low aqueous solubility and have low oral bioavailability.

Such compounds have generally proven to be difficult to formulate for oral administration such that high bioavailabilities are achieved.

High LDL-cholesterol and triglyceride levels are positively correlated, while high levels of HDL-cholesterol are negatively correlated, with the risk for developing cardiovascular diseases.

No wholly satisfactory HDL-elevating therapies exist.

Niacin can significantly increase HDL, but has serious toleration issues that reduce compliance.

As a result, there is a significant unmet medical need for a well-tolerated agent that can significantly elevate plasma HDL levels, thereby reversing or slowing the progression of atherosclerosis.

However, it has proven to be difficult to formulate CETP inhibitors for oral administration such that therapeutic blood levels are achieved.

CETP inhibitors, in general, possess a number of characteristics that render them poorly bioavailable when dosed orally in a conventional manner.

Indeed, the solubility of some CETP inhibitors is so low that it is in fact difficult to measure.

Accordingly, when CETP inhibitors are dosed orally, concentrations of CETP inhibitor in the aqueous environment of the gastrointestinal tract tend to be extremely low, resulting in poor absorption from the GI tract to blood.

The hydrophobicity of CETP inhibitors not only leads to low equilibrium aqueous solubility but also tends to make the drugs poorly wetting and slow to dissolve, further reducing their tendency to dissolve and be absorbed from the gastrointestinal tract.

Various attempts have been made to improve the aqueous concentration of CETP inhibitors, but generally have met with limited success.

Conventional methods of formulation do not provide sufficient solubilities and thus poor oral bioavailabilities have been obtained.

Pre-dissolving CETP inhibitors in hydrophilic solvents such as acetone or PEG followed by delivery as a solution have failed due to inadequate solubility in the solvent or precipitation upon dilution into the aqueous medium .

Suspensions of crystalline drug do not provide sufficient concentrations of drug in solution due to very low aqueous solubilities and therefore yield inadequate blood levels.

However, the solubility (65 mg / mL or less) for some of the most potent and useful CETP inhibitors known to the inventors has limited the dose to 30 mg in a reasonable sized softgel.

This strong dependence of exposure on food could compromise the effectiveness of this medication in the treatment of atherosclerosis if there is a lack of compliance with labeling instructions.

Lack of mixing between oil formulations and the aqueous environment of the GI tract is known to lead to variable gastric emptying and thus variable absorption.

This had the disadvantage of considerable variability in oral bioavailability and PK profile.

Images